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Summary The Con A acceptor glycoproteins of murine and human tumour cell lines revealed by two-
dimensional fingerprinting on polyacrylamide gels fall into two main categories: constant glycoproteins
expressed by all cell lines and variable glycoproteins which are only expressed by particular tumour cell lines.
Since the number of variable glycoproteins on a typical fingerprint is -50, fingerprints from different cell
lines are readily distinguishable. However the variable glycoproteins are not expressed idiosyncratically and
cell lines derived from similar classes of tumours express similar patterns of the variable glycoproteins. For
example, murine fibrosarcomas express patterns which are virtually identical with one another. Characteristic
patterns are also expressed by murine macrophage tumour lines, human carcinomas and human B
lymphoblastoid cells. Thus, the variable glycoproteins behave as a set of linked markers which are indicators
of the type of normal pre-neoplastic precursor cell from which a tumour is derived and appear to be a new
type of marker for tumour cell classification. Antibodies to these glycoproteins could prove useful in tumour
localisation and diagnosis.
Tumour cells express several types of specific
markers which are potentially valuable in tumour
diagnosis and therapy: First, the markers which are
only expressed by cells which grow into malignant
neoplasms (Bramwell & Harris, 1978; Atkinson &
Bramwell, 1981; Dee & Stanbridge, 1981); second,
tumour-specific markers such as the specific
transplantation antigens of chemically-induced
murine fibrosarcomas, which are expressed
idiosyncratically by individual tumours and their
derivative cell lines (Basombrio, 1970); third, the
clonal markers which are normal differentiation
markers determined by the type of normal pre-
neoplastic precursor cells from which each tumour
is derived (Lampson & Levy, 1979; Greaves, 1981).
Although the clonal markers are not absolutely
specific for tumour cells their relatively restricted
distribution amongst normal cells renders them
potentially valuable in the experimental and clinical
investigation of tumours. They can be used in the
classification of tumours since they are indicators of
the type 'of normal precursor cells from which a
tumour has originated. Accurate classification of
tumours is of considerable value in the assessment
of prognosis and treatment of clinical neoplasms.
Because clonal markers are expressed by relatively
few normal cells the abnormal expansion of the
expression of such markers by developing tumours
renders them practically valuable for detection and
localisation (Lampson & Levy, 1979). Finally,
specific antibodies against clonal markers might
even prove useful in the therapy of tumours since
parallel destruction of the normal cells may prove
relatively innocuous. Practical application of this
approach using the specific idiotypes of surface Ig
of B lymphoblastoid tumours is already being
attempted (Stevenson et al., 1977). Thus it is clear
that clonal markers, particularly those expressed at
the cell surface, are a potentially important target
for tumour diagnosis and therapy.
In this report it is shown that the Con A
acceptor glycoproteins expressed by tumour cells
are a new type of specific marker for tumour cells
and have the properties of clonal markers which
could be used as described above in the clinical and
experimental investigation of malignancy.
Materials and methods
Murine tumour cell lines
The following cell lines were kindly provided by
E.S. Lennox and colleagues: C57B11O.MC6A and
MC6B (chemically-induced fibrosarcomas),
C57B110/A.A2, Br.A6, 2R x 5R.A and 5R.A
(Abelson virus-induced lymphomas). Balb/C 3T3
and SV40-3T3 cells were from ICRF London.
P388.D1 and WEH1-3B cells were provided by Dr.
H. Waldmann. P815, EL4, MBL2, LSTRA and
X63, were from the cell collection of the Tumour
Biology Group, Laboratory of Molecular Biology,
Cambridge.
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Human tumour cell lines
HELA and XD87D cells were provided by R.
Johnson: AK cell lines by A. Karpas, HT29 and
CaLu cells by K. Talbot and Raji, Ramos and Bjab
cells by I. McConnell.
Cell culture
Cells were grown in the presence of 10% newborn
calf serum before use. Adherent cells were usually
detached by trypsinisation. Control experiments
showed that trypsinisation does not alter the Con A
acceptor fingerprints of cells (unpublished
observations). Cells were washed 3 x with PBS
before use.
Glycoproteinfingerprinting
This was carried out as described previously (Koch
& Smith, 1982). Briefly, cell lysates in detergent
were subjected to two-dimensional gel
electrophoresis (O'Farrell, 1975) fixed and stained
for protein with Coomassie Blue. The fixed gels
were then stained for Con A acceptor glycoproteins
by immersion into "25I-Con A (Koch & Smith,
1982). Stained gels were washed, dried and
autoradiographed using tungstate enhancing screens
at -70°C. Usually about 2 x 106 cell equivalents
were used in each analysis and autoradiographs
exposed for 24h. The Con A binding components
were identified as glycoproteins because their
detection by '25I-Con A can be inhibited by a-
methyl mannoside, they can be bound to Con A-
agarose and eluted with ac-methyl mannoside, and
they are sensitive to proteolysis by enzymes such as
papain.
Comparison offingerprints
Fingerprints to be compared were prepared in
parallel and compared by direct superimposition on
a light box. Identity of glycoproteins was based on
their relative positions on the maps and differences
in intensity were not considered as significant.
Therefore spots of differing intensity but positional
identity were treated as identical. Horizontal arrays
of spots were treated as single glycoproteins (Koch
and Smith, 1982). Homology between patterns was
calculated from the ratio
Number of common glycoproteins x 2
Total number of glycoproteins on both maps
Results
Con A acceptor glycoproteinsfrom different classes of
tumour cells
Two-dimensional fingerprints of the Con A
acceptor glycoproteins from 4 tumour cell lines
derived from different classes of murine tumours are
shown in Figure 1. The tumours involved are a
myeloma, thymoma, macrophage-type tumour and
an unclassified Abelson virus lymphoma. It is
apparent from even a casual inspection that the
patterns are easily distinguished from one another.
Formal comparisons between the patterns by direct
superimposition of the original maps show that
there is a set of glycoproteins which is present in all
of the maps. These constant glycoproteins are
arrowed on the thymoma map where they are most
obvious because of the relative simplicity of the
general pattern. Two of the constant glycoproteins
(large arrows) are relatively major cellular
constituents since they can also be detected by the
conventional protein stains. In contrast, the other
glycoproteins are only detected by the sensitive
"25I-Con A stain and appear to be minor
constituents of the cells.
Apart from the constant glycoproteins, most of
the rest of the glycoproteins appear to be relatively
specific for one cell line or another. For example,
the thymoma cell line expresses a simple pattern
containing ?% 30 glycoproteins whereas the Abelson
virus lymphoma expresses 70. In general the
number of variable glycoproteins on a map is of the
order of -50 for most murine tumour cell lines
(Koch & Smith, 1982). Thus most of the
glycoproteins on a particular fingerprint are
expressed in a relatively specific manner amongst
murine tumour cell lines and can be used to identify
such cell lines, at least provisionally.
Cell lines derived from human tumours also
express diverse patterns of glycoproteins. Figure 2
shows the fingerprints of Con A acceptor
glycoproteins obtained from an EBV+ B
lymphoblastoid line, an EBV- lymphoblastoid line,
the Hela line and a fibrosarcoma line. Once again it
is apparent that the patterns are significantly
different from one another. However as in the case
of the murine cell lines there is a set of constant
glycoproteins which are expressed by all cell lines.
Interestingly, the constant glycoproteins of human
tumour cell lines appear to be very similar to those
of murine cells. Furthermore, the maps show that
the number of glycoproteins expressed by different
human tumour cell lines can also vary over a wide
range and the number of variable glycoproteins
usually exceeds that of the constant glycoproteins.
Con A acceptor glycoproteins of tumour cell lines
from similar types oftumours
Figure 3 shows the patterns of Con A acceptor
glycoproteins expressed by two murine tumour cell
lines derived from chemically-induced
fibrosarcomas. In contrast to the patterns shown inCONCANAVALIN A ACCEPTOR GLYCOPROTEINS
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Figure 1 Con A acceptor glycoproteins of murine cell lines from different types of tumours. Fingerprints
were prepared from 2 x 106 cell equivalents of each cell line as described in Materials and methods. In all
maps the origin is at the top left hand corner. The arrows on the MBL2 map show the constant glycoproteins
of murine cells (see text). The cell lines were MBL2 thymoma (Glynn et al., 1968), P815 mastocytoma (Dunn
& Potter, 1957), X63 myeloma (Horibata & Harris, 1970), C57B110, 2Rx5R Al Abelson lymphoma (E.S.
Lennox, personal communication).
Figure 1 these patterns are very similar to one
another. The diagram showing the spots which are
common to both cell lines includes virtually all the
spots on the maps, making the homology between
the two patterns close to 100%. Repeated mapping
of these two cell lines has failed to reveal significant
differences between their glycoprotein patterns even
though the two cell lines are known to express
different tumour-specific transplantation antigens
(Sikora et al., 1979). Furthermore the two cell lines
grow with a slightly different morphology during
culture. The latter observations are important since
they show that the unusual similarity between the
glycoprotein patterns does not reflect inadvertent
cross-contamination of the two cell lines.
A second example of high homology between
glycoprotein patterns of independently-isolated
tumour cell lines was the two Abelson virus-induced
murine lymphomas shown in Figure 4. As the
diagram shows, there are .65 glycoproteins which
are expressed by both cell lines, corresponding to a
homology of >75% between the two patterns of
glycoproteins. Since the two cell lines had been
induced in strains of mice with different H-2
antigens, which are detectable on the respective
maps (Figure 4) it was possible to exclude cross-
contamination as the basis of the similarity between
the glycoproteins. It was possible that the similarity
reflected the fact that both cell lines were obtained
from Abelson virus tumours. However, other
Abelson virus tumour cell lines produced in the
same laboratory by the same protocol did not
express the same pattern of glycoproteins (Figure 4).
Subsequent studies showed that a common factor
between the two cell lines with homologous
patterns was that both were derived from
macrophage-like cells. The formal test for this was
the expression of the Mac-1 antigen detected by the
monoclonal M1/70 antibody (Springer et al., 1979).
This antigen is expressed by the two homologous
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Figure 2 Con A acceptor glycoproteins from human cell lines from different classes of tumours. The arrows
on the AK330 map show the constant glycoproteins of human cells (see text). All maps in this set were not
prepared in parallel. The cell lines used were HeLa carcinoma, XPD87D fibrosarcoma (R. Johnson, personal
communication), AK328 B lymphoblastoid, AK330 leukaemia (A. Karpas, personal communication).
Figure 3 Con A acceptor glycoproteins from the murine fibrosarcoma cell lines C57B110 MC6A and
C57B110 MC6B (Sikora et al., 1979). The diagram to the right shows the spots which are common to both
maps.CONCANAVALIN A ACCEPTOR GLYCOPROTEINS
Figure 4 Con A acceptor glycoproteins from murine macrophage-like tumour cell lines C57BrlOBlA6 and
C57B1lOA.A2. The diagram (upper right) shows the spots which are common to both maps (upper panels).
The maps from two other Abelson virus induced non-macrophage tumour cell lines are also included (lower
panels) to show that all Abelson virus tumour cell lines do not yield the same pattern. The H2 antigens were
identified by comparative mapping with normal murine lymphocytes from congenic mice (unpublished data).
Abelson virus tumour cell lines at levels comparable
to that on other macrophage-like tumour cells e.g.
P388D1 (Koren et al., 1975). The homologous cell
lines also express other macrophage-like properties
such as adhesion to substrata, high-levels of Fc
receptors and ingestion of particles (unpublished
observations). Therefore, it was concluded that both
homologous Abelson virus tumour lines were
derived from macrophage-like tumours.
Human tumour cell lines also exhibit a similar
correlation between their glycoprotein patterns and
the type of normal precursor cell from which they
are derived. Figure 2 showed that the EBV+ B
lymphoblastoid line gave a different pattern to that
from other types of tumour cell lines. However all
EBV+ B lymphoblastoid lines derived from
peripheral blood express glycoprotein patterns
which are clearly very similar to one another
(Figure 5). This pattern is not expressed by EBV-
leukaemic cell lines (e.g. Molt 4, AK 45) or by
EBV+ cell lines derived from Burkitt's lymphomas
(e.g. Raji, Ramos) indicating that it does not merely
reflect the EBV infection of the cells. Studies with
the BJAB cell line after in vitro infection with EBV
showed that the only novel glycoprotein expressed
after infection was the arrowed set of spots (Figure
4). Thus, it appears that the pattern expressed by
these homologous cell lines reflects the fact that
they are derived from the sub-population of B
lymphocytes which are readily amenable to in vitro
culture following endogenous infection with EBV.
Tumour cell lines derived from human
carcinomas also show a significantly greater
homology with one another than unrelated tumour
cell lines. Figure 6 shows the patterns obtained
from the lung carcinoma line, CaLu-1, and the
colon adenocarcinoma line, HT29. The diagram
shows the spots which are common to both cell
lines. This corresponds to a homology of >50%
between the two cell lines. In a similar comparison
with another adenocarcinoma line, Ger (Grant et
al., 1979), the homology was 55% and 75%
respectively (unpublished data). Sufficiently detailed
comparison has not yet been effected to determine
whether the greater homology between the two
adenocarcinoma lines was significant. However, it is
clear that cell lines derived from epithelial tumours
express significantly greater similarity between their
glycoprotein patterns than with the other types of
tumour cell lines examined so far.
These studies show that there is a close
correlation between the pattern of variable
glycoproteins of a tumour cell line and the type of
tumour from which it was derived.
Specificity of the variable con A acceptor
glycoproteins as markers for particular classes of
tumour cells
In order to determine the reliability of the Con A
acceptor glycoproteins as markers for the
classification of tumour cells an extensive cross-
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Figure 5 Con A acceptor glycoproteins from EBV+ human B lymphoblastoid cell lines. All cell lines were
isolated from peripheral blood, and were kindly prepared by A. Karpas. The arrows show the only spots
which are induced when the EBV- BJAB cell lines are infected by EB virus in vitro (unpublished data).
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Figure 6 Con A acceptor glycoproteins from human carcinoma cell lines. The cell lines were the lung
carcinoma CaLu-l and the colon carcinoma HT29 (Fogh et al., 1977). The diagram on the right shows the
spots which are common to both cell lines.CONCANAVALIN A ACCEPTOR GLYCOPROTEINS 533
comparison was carried out between 15 murine
tumour cell lines. Pairs of maps were superimposed
and the homologous glycoproteins identified by
their relative positions on the maps. Three broad
levels of homology were defined. First, homology
levels of up to 25% between patterns. These include
cell lines with glycoprotein patterns which are easily
distinguished e.g. Figure 1. Most of the homology is
accounted for by the constant glycoproteins which
are present on all maps. Second, cell lines with
homology of -50%. These are exemplified by cells
such as the human carcinoma lines which need to
be examined formally to assess their degree of
similarity. Third, the cell lines such as the murine
fibrosarcomas shown in Figure 2 which show an
obvious similarity between their glycoprotein
patterns, i.e. >75%.
Figure 7 summarises the results of the cross-
comparisons between the patterns of Con A
acceptor glycoproteins from murine tumour cell
lines. Out of a total of 71 separate comparisons, 55
showed <25% homology. This confirms the general
feature of the glycoprotein fingerprints i.e. their
relative specificity for particular cell lines. Figure 7
also shows that all the fibrosarcoma lines showed a
high degree of homology with one another but not
with any other type of tumour cell. The
fibrosarcoma cell lines used were obtained from
chemically-induced (MC6A and MC6B) embryonic
(STO) and virally-induced (SV40-3T3) fibro-
sarcomas showing that the specific pattern was
determined by the type of cell involved not the
mode of tumour induction. Similarly, the Abelson
virus macrophage tumour lines only showed a high
degree of homology with the P388D1 line which is
the prototype murine macrophage tumour line
(Koren et al., 1975). These cell lines also showed
intermediate homology with the myelomonocytic
WEH1-3B line. The latter also expresses the Mac-i
antigen (unpublished observation) and can be
induced to differentiate into macrophages and
granulocytes (Metcalf, 1979).
The only apparent anomaly encountered so far in
the correlation between the glycoprotein pattern
expressed by a cell line and the class of tumour
from which it was derived was the P815 cell line.
This has been classified as a mast cell neoplasm
(Dunn & Potter, 1957) and yet it shows significant
homology with the macrophage-type tumour lines.
This might mean that the mast cell and macrophage
neoplasms actually express similar patterns of
glycoproteins or that the subline of the P815 line
used was a contaminant macrophage-type cell.
Studies are in progress to distinguish between these
possibilities.
Apart from the above example, it appears that
the pattern of Con A acceptor glycoproteins
expressed by a tumour cell line is specific for the
type of tumour from which it was derived.
Discussion
These studies confirm that the Con A acceptor
glycoproteins of cultured cells from both murine
and human tumours are a relatively specific
characteristic ofeach cell line. Broadly speaking, the
glycoproteins on each fingerprint can be divided
into two classes: constant glycoproteins which are
expressed by all cell lines and variable glycoproteins
which are not. Although not established formally, it
appears that the constant glycoproteins from both
human and murine sources are very similar. In
contrast, the variable glycoproteins are an
unusually specific characteristic of tumour cells and
with the exception of cell lines derived from closely
related tumours they are usually very different from
different cell lines. Because the variable
glycoproteins are usually the majority in a
particular fingerprint the patterns from cell lines
from unrelated tumours are easily distinguished
from one another, rather as the peptide fingerprints
from different proteins can be used to distinguish
between proteins. Furthermore, just as peptide
maps can be used to identify proteins the
glycoprotein fingerprints can be used to identify
various cultured cell lines. With the enormous
proliferation of cultured tumour cell lines for
laboratory investigation the problems of
identification and cross-contamination have
increased considerably (Gartler, 1968). Whilst
enzyme (Povey et al., 1976) and histocompatibility
typing (O'Toole et al., 1982) have proved very
useful in cell identification they can be laborious
and require specialised laboratory investigators. In
contrast gel fingerprinting is virtually routine and
can be adopted by almost any laboratory. One
requirement of this approach to cell identification is
that the phenotype should be stable during in vitro
cell culture. Studies carried out so far show that
this is indeed the case and in one detailed
investigation of the stability of the glycoprotein
pattern from a pancreatic adenocarcinoma
(unpublished data) no significant instability was
detected. Therefore the two-dimensional fingerprints
of the Con A acceptor glycoproteins have the
specificity and stability required to be useful in the
identification of cultured tumour cell lines.
The most significant feature of the variable Con
A acceptor glycoproteins of both murine and
human tumour cell lines is the fact that they are
not expressed in a completely idiosyncratic fashion.
Thus, independently-isolated tumour cell lines can
express very similar or even identical patterns of
glycoproteins e.g. the MC6A and MC6B534 G.L.E. KOCH & M.J. SMITH
T1E UO. 0-25 %
U 1 * * 25-75 %
T3 L 175-100 %
Abl DElHI
Ab2 .I°ILILIE
Fl[H EIIELI
F2 D L L I I
F3L Suml0
F.4LI. 1111 l
MFi 0I El|
Ab3L0ILIULIL0I 0L0ILIUEEE
Ab4HLILIHLILILI 0DLI lEE**
F~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MF2 IEEE
* T T3 Ab1 F1 F3 Ms Ab3 MF2
T2 My Ab2 F2 F4 MF Ab4
Figure 7 Cross comparison of the Con A acceptor glycoprotein fingerprints of 15 murine tumour cell lines. Comparison
was carried out between pairs of maps prepared in parallel by direct superimposition and homology, estimated as
described in Materials and methods. The cell lines used were: T1 MBL2; T2 EL4; T3 BW5147 (Glynn et al., 1968); My
X63 Ag8 (Horibata & Harris, 1970); AbI C57B110 5R; Ab2 C57B110 2R x 5R; Ab3 C57Bl 10 A.A6; Ab4 C57B IlOBrA6;
Fl C57Bl1OMC6A; F2 C57Bl1OMC6B (Sikora et al., 1979); F3 SV40-Balb/c 3T3; F4 STO (Ware & Axelrad, 1972);
Ms P815 (Dunn & Potter, 1957); MF1 WEH1-3B (Warner et al., 1969); MF2 P388D1 (Koren et al., 1975).
T=thymoma, My =myeloma, Ab =Abelson lymphoma, F =fibroblastoid, Ms =mastocytoma, MF =macrophage.CONCANAVALIN A ACCEPTOR GLYCOPROTEINS 535
fibrosarcoma lines. This indicates that the set of
variable glycoproteins in a particular pattern is
expressed as a linked group of markers.
Furthermore, these linked markers correlate with
the type of tumour from which the cell lines are
derived. Thus, the murine fibrosarcomas, murine
macrophages, human EBV+ lymphoblastoid lines
and human carcinoma lines express patterns of
glycoproteins which appear to be characteristic for
cell lines derived from each class of tumour.
Furthermore, in the murine fibrosarcomas the
characteristic pattern of Con A acceptor
glycoproteins is expressed by cell lines derived from
tumours induced by different agents indicating that
the mode of induction does not play a significant
role in determining the pattern.
The three features of the Con A acceptor
glycoproteins mentioned above, viz. their expression
as a linked set, their correlation with the type of
tumour involved and the apparent irrelevance of the
tumour-inducing agent, all indicate that the
patterns expressed by tumour cell lines are largely
determined by the type of normal precursor cell
from which each tumour is derived. This in turn
suggests that the variable glycoproteins are
indicators of the pathway of differentiation to which
the pre-neoplastic precursor cell was committed.
The interesting feature of the Con A acceptor
glycoproteins as differentiation markers is the fact
that each cell line expresses such a large number of
such specific markers. Thus most cell lines.
particularly the murine fibrosarcomas and
macrophages express >50 separate Con A acceptor
glycoproteins which are more or less characteristic
for such cells. The biological function of these
glycoproteins is not known. However, it has been
speculated (Hood et al., 1977) that cells might
express surface markers at different stages of their
normal lineages which could be important in their
precise location in the organism and in the
recognition of other cells and extracellular matrices.
It is possible that the Con A acceptor glycoproteins
serve such a role during normal development.
The linkage of the pattern of variable Con A
acceptor glycoproteins to the state of differentiation
of the normal pre-neoplastic precursor cell from
which tumour cells are derived indicates that they
may be particularly useful as specific markers for
tumour cell classification. From this point of view
they have some significant advantages. Thus, each
class of tumour cell appears to express a large
number of these markers all of which are revealed
by a single analysis. Since the markers concerned
are glycoproteins it is likely that many of them are
expressed on cell surfaces, although the exact extent
of this is not yet known. Consequently, specific
antibodies may be used in simple binding assays to
identify and classify the corresponding tumour cells.
Of particular significance is the apparent specificity
of the glycoprotein fingerprint for tumour cells
derived from the same lineage but from precursor
cells of differing maturity. For example the WEH1-
3B cell, which is believed to originate from a
relatively immature cell in the macrophage lineage,
can be distinguished from the P388D1 cell which
appears to be derived from a more mature cell. This
may prove to be the most significant aspect of the
Con A acceptor glycoproteins as tumour cell
markers. Conventional classification of tumour cells
is largely based on their expression of
characteristics of mature cells from a particular
lineage. However tumours probably arise from
relatively immature cells (Potter, 1978; Mintz &
Fleischmann, 1981) which may express mature
markers to varying extents. In contrast, the variable
glycoproteins do not appear to be expressed by
mature cells such as lymphocytes and macrophages
(manuscript in preparation) and may therefore be
specific for the immature normal precursor cells.
Thus, they could prove more specific as
classification markers than the conventional
markers being used currently.
Finally it is worth noting that although the Con
A acceptor glycoproteins appear to be indicators of
normal cell differentiation they may nevertheless
prove useful as specific antigens for tumour
diagnosis, localisation and therapy. This is based on
the view that markers which have a relatively
restricted expression amongst normal cells can be
just as useful as classical tumour-specific markers
because the clonal expansion which occurs during
tumour growth will generate a corresponding
expansion of the specific marker (Lampson & Levy,
1979). The use of Ig idiotypes in B lymphoblastoid
tumours has often been quoted to exemplify this
approach (Stevenson et al., 1977). Thus, antibodies
against the variable Con A glycoproteins could
prove of considerable value in clinical investigations
of tumours.
We thank all our colleagues, particularly A. Lowe and E.
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